News

Read our News and Insights

Featured news

Helsinn appoints Giacomo Braglia to the Board of Directors

Helsinn Healthcare & InVirtuoLabs sign a Strategic Collaboration in AI-Driven Drug Discovery

Helsinn announces European Commission approval of AKYNZEO® Oral Suspension

Helsinn and MagnaPharm enter long-term agreement for AKYNZEO® and ALOXI® across five Central and Eastern European countries

Helsinn and ESTEVE expand their partnership extending the Distribution and Licence Agreement for AKYNZEO® and ALOXI® to Austria

Helsinn announces new Executive Leadership Team as it celebrates 50 years

Load More...

Exiting the US site

You are about to enter a website not intended for a US audience.
Please confirm your acceptance to continue

Continue
Cancel

Entering the US site

You are about to enter a website only intended for a US audience.
Please confirm your acceptance to continue.

Continue
Cancel

You are now leaving helsinn.com

Please click ‘Continue to external site’ if you want to continue.